ReviewJournal of the American College of Cardiology2024
Artificial Intelligence in Cardiovascular Clinical Trials.
Review in Journal of the American College of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Application of Large Language Models in Chronic Disease Care: Mixed Methods Systematic Review and Thematic Synthesis.Journal of medical Internet research · 2026Pooled it
- Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial.Nature medicine · 2026Trial
- From Automated ECG Interpretation to Multimodal Cardiovascular Intelligence: The Evolution of Artificial Intelligence in Cardiovascular Medicine.Medical sciences (Basel, Switzerland) · 2026Review
- Embedded transparency in artificial intelligence: a prerequisite for equity and representation in AI-enabled clinical trials.NPJ digital medicine · 2026Article
- Advances in cardiac devices and bioelectronics augmented with artificial intelligence.The Journal of physiology · 2026Review
- Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Clinically Relevant Discordance Between SCORE2 and REGICOR in Spanish Workers: Implications for Cardiovascular Risk Reclassification in Primary Prevention.Medical sciences (Basel, Switzerland) · 2026Article
- Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical Trials.Journal of the American College of Cardiology · 2026Article
- mRNA medicine for cardiovascular disease.Nature cardiovascular research · 2026Review
- Precision cardiovascular medicine with big data and AI.NPJ digital medicine · 2026Review
- The potential of artificial intelligence in clinical trials.European journal of clinical investigation · 2026Review
- Synthetic artificial intelligence in cardiology: from generative models to clinical applications.European heart journal open · 2026Review
- Artificial intelligence in cardiology: a narrative review with focus on patient outcomes.Cardiovascular diagnosis and therapy · 2026Review
- Myocardial ischemia-reperfusion injury after acute myocardial infarction: spatiotemporal mechanisms and endotype-matched multi-target modulation by compounds from traditional Chinese medicine.Frontiers in cardiovascular medicine · 2026Review
- Multidimensional cardiac functional phenotyping beyond ejection fraction: a multimodality imaging framework for cardiovascular care.Frontiers in cardiovascular medicine · 2026Review
- Exploring the feasibility of using artificial intelligence to simulate the placebo arm of randomized clinical trials.Postgraduate medical journal · 2025Article
- [Progress in the application of artificial intelligence in assisted reproduction].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Review
- Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Immunosenescence: signaling pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- Molecular Diagnostics in Heart Failure: From Biomarkers to Personalized Medicine.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Randomized clinical trials are the gold standard for establishing the efficacy and safety of cardiovascular therapies. However, current pivotal trials are expensive, lengthy, and insufficiently diverse. Emerging artificial intelligence (AI) technologies can potentially automate and streamline clinical trial operations. This review describes opportunities to integrate AI throughout a trial's life cycle, including designing the trial, identifying eligible patients, obtaining informed consent, ascertaining physiological and clinical event outcomes, interpreting imaging, and analyzing or disseminating the results. Nevertheless, AI poses risks, including generating inaccurate results, amplifying biases against underrepresented groups, and violating patient privacy. Medical journals and regulators are developing new frameworks to evaluate AI research tools and the data they generate. Given the high-stakes role of randomized trials in medical decision making, AI must be integrated carefully and transparently to protect the validity of trial results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.